The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
@article{Sarno2000TheEO, title={The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas}, author={A. di Sarno and M. L. Landi and P. Marzullo and C. Di Somma and R. Pivonello and G. Cerbone and G. Lombardi and A. Colao}, journal={Clinical Endocrinology}, year={2000}, volume={53} }
To compare effectiveness and tolerability of quinagolide (CV 205–502) and cabergoline (CAB) treatments in 39 patients with prolactinoma.
Topics from this paper
77 Citations
Factors determining the remission of microprolactinomas after dopamine agonist withdrawal
- Medicine
- Clinical endocrinology
- 2010
- 28
Management of resistant prolactinomas
- Medicine
- Nature Clinical Practice Endocrinology &Metabolism
- 2006
- 37
Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy
- Medicine
- Clinical endocrinology
- 2007
- 71
Dopamine receptor agonists for treating prolactinomas
- Medicine
- Expert opinion on investigational drugs
- 2002
- 112
Hyperprolactinemia and prolactinomas.
- Medicine
- Endocrinology and metabolism clinics of North America
- 2008
- 147
References
SHOWING 1-10 OF 37 REFERENCES
Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study
- Medicine
- Clinical endocrinology
- 1992
- 49
Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine
- Medicine
- Clinical endocrinology
- 1994
- 31
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 1997
- 225
- PDF
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 1992
- 43
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
- Medicine
- 1992
- 40
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients
- Medicine
- Journal of endocrinological investigation
- 1994
- 27
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 1986
- 119
Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 1990
- 24